Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Khalid Arshad

Child & Adolescent Psychiatry Kankakee, IL Medical Doctor

NPI 1306259817 CMS profile 4044612

400 N Wall St Ste B402, Kankakee, IL 60901

Open in the dashboard

General payments

$7,883

404 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Khalid Arshad of Kankakee, IL is reported in the CMS Open Payments database as having received $7,883 across 404 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,610 78
2024 General $1,996 99
2023 General $1,775 97
2022 General $1,537 78
2021 General $583 31
2020 General $123 6
2019 General $258 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Khalid Arshad
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Khalid Arshad were reported at $1,610. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Khalid Arshad Child & Adolescent Psychiatry median Middle half National median
2019 $258 $129 $42–$419 $163
2020 $123 $81 $28–$226 $114
2021 $583 $115 $31–$326 $132
2022 $1,537 $124 $40–$382 $149
2023 $1,775 $130 $45–$420 $160
2024 $1,996 $141 $42–$490 $164
2025 $1,610 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $1,267 70 payments
  2. Neurocrine Biosciences, Inc. $674 30 payments
  3. Indivior Inc. $572 23 payments
  4. Teva Pharmaceuticals USA, Inc. $555 37 payments
  5. Supernus Pharmaceuticals, Inc. $551 26 payments
  6. ITI, Inc. $542 30 payments
  7. Alkermes, Inc. $478 24 payments
  8. AbbVie, Inc. $379 14 payments
  9. Ironshore Pharmaceuticals Inc. $376 18 payments
  10. Janssen Pharmaceuticals, Inc $337 18 payments
  11. Other $2,151 114 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,855 403 payments
  2. Education $27 1 payment
Products named General payments · program years 2019–2025
  1. ABILIFY MAINTENA $678 40 payments
  2. INGREZZA $674 30 payments
  3. PERSERIS $572 23 payments
  4. ARISTADA Cns $478 24 payments
  5. ARISTADA Cns $478 24 payments
  6. LYBALVI $440 22 payments
  7. REXULTI $407 20 payments
  8. CAPLYTA $391 21 payments
  9. ARISTADA Cns $386 19 payments
  10. ARISTADA Cns $386 19 payments
  11. Other $5,235 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

192

Median for Psychiatry: 574

Drug cost

$5,387

Median for Psychiatry: $27,624

Branded share of claims

16.1%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aripiprazole Generic 19 $2,182
Quetiapine Fumarate Generic 22 $698
Bupropion Xl Bupropion Hcl Brand 15 $541
Fluoxetine Hcl Generic 14 $397
Trazodone Hcl Generic 30 $372
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 16 $317
Risperidone Generic 20 $305
Duloxetine Hcl Generic 15 $237
Escitalopram Oxalate Generic 15 $168
Lorazepam Generic 12 $89

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$6,818

Medicare's payments for the services billed

Medicare patients

55

Average age 60

Services billed

106

26 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 67%
Arthritis 49%
Ischemic heart disease 40%
Diabetes 36%
Alzheimer's or dementia 31%
COPD 27%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $264
$264 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $186
$186 — —
PERSERIS
  • Indivior Inc. $181
$181 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $164
$164 — —
CAPLYTA
  • ITI, Inc. $144
$144 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

404 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record